C Diff Treatment

Background: Clostridium difficile (C. difficile) is a common cause of hospital-acquired diarrhea. It is associated with significantly higher mortality and morbidity in addition to the cost-effec...

The Peggy Lillis Foundation’s Advocates Council is a nationwide network of individuals whose lives have been impacted by #cdiff Join the Advocates Council to use your voice and make a difference 👉https://t.co/n71VkuYlD5 pic.twitter.com/HFRxlGfwWG— Peggy Lillis Fund (@PeggyFund) May 17, 2023

Clostridioides difficile colonizes up to 30-40% of community-dwelling adults without causing disease [1][1], [2][2]. C. difficile infections (CDIs) are the leading cause of antibiotic-associated diarrhea in the U.S. [3][3], [4][4] and typically develop in individuals following disruption of the gut microbiota due to antibiotic or chemotherapy treatments [2][2]. Further treatment of CDI with antibiotics is not always effective and can lead to antibiotic resistance and recurrent infections (rCDI) [5][5], [6][6]. The most effective treatment for rCDI is the reestablishment of an intact microbiota via fecal microbiota transplants (FMTs) [7][7]. However, the success of FMTs has been difficult to generalize because the microbial interactions that prevent engraftment and facilitate the successful clearance of C. difficile are still only partially understood [8][8]. Here we show how microbial community-scale metabolic models (MCMMs) accurately predicted known instances of C. difficile colonization susceptibility or resistance. MCMMs provide detailed mechanistic insights into the ecological interactions that govern C. difficile engraftment, like cross-feeding or competition involving metabolites like succinate, trehalose, and ornithine, which differ from person to person. Indeed, three distinct C. difficile metabolic niches emerge from our MCMMs, two associated with positive growth rates and one that represents non-growth, which are consistently observed across 14,862 individuals from four independent cohorts. Finally, we show how MCMMs can predict personalized engraftment and C. difficile growth suppression for a probiotic cocktail (VE303) designed to replace FMTs for the treatment rCDI [9][9], [10][10]. Overall, this powerful modeling approach predicts personalized C. difficile engraftment risk and can be leveraged to assess probiotic treatment efficacy. MCMMs could be extended to better understand personalized engraftment of other opportunistic bacterial pathogens, beneficial probiotic organisms, or more complex microbial consortia. ### Competing Interest Statement The authors have declared no competing interest. [1]: #ref-1 [2]: #ref-2 [3]: #ref-3 [4]: #ref-4 [5]: #ref-5 [6]: #ref-6 [7]: #ref-7 [8]: #ref-8 [9]: #ref-9 [10]: #ref-10

The Clostridioides difficile study was presented at Digestive Disease Week in Chicago.

I am a healthy active older woman. On March 1, 2019 I had an explosive episode of diarrhea, out of the blue, no idea what caused it. The smell was indescribable, like nothing I had ever experienced in my long life. That was the beginning of a long saga I’ll …

Every year, thousands of patients across the United States are impacted by the effects of hospital-onset Clostridioides difficile (C. diff) infections (HO-CDIs). In this webinar, we will examine the limitations of current interventions to prevent transmission of C. diff. We will also present the manner in which an effective environmental hygiene program to reduce HO-CDI is implemented and the critical role EVS personnel played.

Clostridioides difficile (C. difficile) is a bacterium that can infect the large intestine, with symptoms ranging from diarrhea to life-threatening colon damage. A study published May 11 in PLOS Biology ...

Researchers say antibiotics don't always work against clostridioides difficile (C. diff) because of their interaction with gut bacteria. Here's some treatments to try to battle these infections.

Patients with C. difficile who received clonal bacteria populations via biotherapeutic injection were able to repopulate their microbiota with commensal bacteria.

Investigators in Canada found no evidence to support extending treatment for Clostridioides difficile infection for patients on concurrent antibiotics

Clostridioides difficile infection (CDI) is the most lethal of the five CDC urgent public health treats, resulting in 12,800 annual deaths in the United States alone [Antibiotic Resistance Threats in the United States, 2019 (2019), www.cdc.gov/DrugResistance/Biggest-Threats.html]. The …

The infection causes diarrhea and inflammation of the colon, and it can be difficult to get rid of it.

This is a literature review describes Crohn's disease (CD) concomitant with breast cancer and summarizes possible common pathogenic mechanisms shared by the two diseases involving the IL-17 and NF-κB signaling pathways. Inflammatory cytokines including TNF-α and Th17 cells in CD patients can induce …

Racial differences in Clostridioides difficile infection (CDI) outcomes have been reported. In this study, minoritized patients with CDIs had prolonged hospitalizations and increased intensive care unit admissions. Chronic kidney disease was shown to partially mediate the relationship between …

Emergency Medicine’s #1 Journal Publication: Clinical advances and trends from the most trusted emergency medical news source in emergency medicine.

Clostridioides difficile infection (CDI) is one of the most common hospital-acquired infections. Its incidence has increased during the last decade in the community among individuals with no previous risk factors; however, morbidity and mortality are still considered high in elderly patients. Oral V …

Clostridioides difficile infection (CDI) causes substantial morbidity and mortality worldwide with limited antibiotic treatment options. Ridinilazole is a precision bisbenzimidazole antibiotic being developed to treat CDI and reduce unacceptably high rates of infection recurrence in patients. Althou …

Clostridioides difficile infections (CDIs) remain a healthcare problem due to high rates of relapsing/recurrent CDIs (rCDIs). Breakdown of colonization resistance promoted by broad-spectrum antibiotics and the persistence of spores contribute to rCDI. Here, we demonstrate antimicrobial activity of t …

C. difficile or Clostridioides difficile infection (CDI) is currently one of the major causes of epidemics worldwide. Toxin B from Clostridioides difficile toxin B (TcdB) infection is the main target protein inhibiting CDI recurrence. Clinical research suggested that bezlotoxuma …

No significant difference in rates of recurrence or new onset VRE were observed between SDT and EDT in HA-CDI patients.

A team of investigators from Mass General Brigham’s founding members, Brigham and Women’s Hospital and Massachusetts General Hospital, has identified metabolic strategies used by Clostridioides difficile to rapidly colonize the gut and new treatments for it.

A hospital reviewed both treatments in a real-world clinical setting to determine the effectiveness in preventing early and late recurrences.

A live biotherapeutics product used alongside antibiotics can help combat C. difficile infection (CDI).

This was the first study to compare clinical outcomes in carbapenemase-producing (CP-CRE) and non–carbapenemase-producing (nCP-CRE) infections.

There are minimal differences between TAC and DLI with antegrade colonic lavage for fulminant CDI in terms of postoperative morbidity and mortality. Healthcare resource utilization, however, is significantly improved when patients undergo TAC as evidenced by clinically important decreases in total a …

How should we determine the role of bezlotoxumab for pediatric Clostridioides difficile infection?

Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, reviews emerging therapeutics being investigated for the prevention and treatment of Clostridioides difficile infection (CDI).

From travel concerns to feeling isolated, discover how three UC warriors overcame their fears.

Can't wait to speak on the topic of "#MedicalGaslighting & #Cdiff: Utilizing Your Voice Effectively."#infectiousdisease #healthcare #advocacy #awareness #LetsSaveLives https://t.co/oLXKAfeCed— Dr. Melissa Geraghty, Psy.D. (She/Her/Dr)🦓🦒🦄😷♿ (@MindfulDrG) April 19, 2023